Skip to main content

Table 7 Missed interventions for prevention and control of NCDs in Iran

From: Assessment and prioritization of the WHO “best buys” and other recommended interventions for the prevention and control of non-communicable diseases in Iran

ObjectiveMissed interventionsType of intervention
11.3 Strengthen international cooperation for resource mobilization, capacity-building, health workforce training and exchange of information on lessons learned and best practicesOverarching/enabling policy interventions.
22.2 Assess national capacity for prevention and control of NCDs
44.2 Explore viable health financing mechanisms and innovative economic tools supported by evidence
44.7 Develop and implement a palliative care policy, including access to opioids analgesics for pain relief, together with training for health workers
33.38 Limiting portion and package size to reduce energy intake and the risk of overweight/obesityOther recommended interventions from WHO guidance (cost-effective analysis not available).
33.45 Ensure that macro-level urban design incorporates the core elements of residential density, connected street networks that include sidewalks, easy access to a diversity of destinations and access to public transport
44.16 Anticoagulation for medium-and high-risk non-valvular atrial fibrillation and for mitral stenosis with atrial fibrillation
44.31 Oral cancer screening in high-risk groups (for example, tobacco users, betel-nut chewers) linked with timely treatment
44.10 Treatment of new cases of acute myocardial infarction** with either: acetylsalicylic acid, or acetylsalicylic acid and clopidogrel, or thrombolysis, or primary percutaneous coronary interventions (PCI)Effective interventions with cost-effectiveness analysis >I$ 100 per DALY averted in LMICs.
44.12 Primary prevention of rheumatic fever and rheumatic heart diseases by increasing appropriate treatment of streptococcal pharyngitis at the primary care level
44.13 Secondary prevention of rheumatic fever and rheumatic heart disease by developing a register of patients who receive regular prophylactic penicillin
44.26 Vaccination against human papillomavirus (2 doses) of 9–13-year-old girls‘Best buys’: Effective interventions with cost-effectiveness analysis = I$ 100 per DALY averted in LMICs.